[Not Available].

Roman Vion, Maxime Fontanilles, Frédéric Di Fiore, Florian Clatot

Journal: Bulletin du cancer 2022;108(11S):11S46-11S54

PMID: 34969515

Full Text on Elsevier Science View on PubMed

Abstract

The tumor biopsy remains essential for breast cancer diagnosis and characterization. Indeed, the treatment is decided according to histological subtype, and according to the presence of targetable molecular alterations. Notably, the presence of hormone receptors, ERBB2 hyperexpression or the existence of PIK3CA or ESR1 mutations are among the alterations commonly investigated. But these biological characteristics are determined only partially by tumor biopsy, due to tumor heterogeneity or tumor plasticity that happens spontaneously or under treatment. Liquid biopsy, and in particular circulating tumor DNA and circulating tumor cells, is a non-invasive method to identify and characterize the presence of cancer in the blood. The aim of this review is to determine the value of liquid biopsy to enhance or replace the data provided by a tumor biopsy.

Address: Département d'oncologie médicale, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Université de Rouen.; Département d'oncologie médicale, centre Henri-Becquerel, 1, rue d'Amiens, 76000 Rouen, France Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Université de Rouen. Electronic address: [email protected].

DOI: 10.1016/S0007-4551(21)00636-6